Vortioxetine

Generic Name
Vortioxetine
Brand Names
Brintellix, Trintellix
Drug Type
Small Molecule
Chemical Formula
C18H22N2S
CAS Number
508233-74-7
Unique Ingredient Identifier
3O2K1S3WQV
Background

Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of se...

Indication

用于治疗重度抑郁症成人患者。

Associated Conditions
Major Depressive Disorder (MDD)
Associated Therapies
-
Clinical Trials
Related News

Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder

Phase 3
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Placebo
Drug: Vortioxetine
First Posted Date
2011-05-17
Last Posted Date
2014-11-11
Lead Sponsor
Takeda
Target Recruit Count
366
Registration Number
NCT01355081

Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotransmitters in Healthy Male Adults

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Vortioxetine
Drug: Placebo
First Posted Date
2011-02-18
Last Posted Date
2013-12-13
Lead Sponsor
Takeda
Target Recruit Count
17
Registration Number
NCT01299805

Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder

Phase 2
Completed
Conditions
Depressive Disorder, Major
Interventions
Drug: Placebo
Drug: Vortioxetine
First Posted Date
2010-12-07
Last Posted Date
2013-12-18
Lead Sponsor
Takeda
Target Recruit Count
600
Registration Number
NCT01255787

Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Phase 3
Completed
Conditions
Depressive Disorder, Major
Interventions
Drug: Placebo
Drug: Vortioxetine
First Posted Date
2010-08-11
Last Posted Date
2013-12-18
Lead Sponsor
Takeda
Target Recruit Count
469
Registration Number
NCT01179516

Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Phase 3
Completed
Conditions
Depressive Disorder, Major
Interventions
Drug: Placebo
Drug: Vortioxetine
First Posted Date
2010-07-15
Last Posted Date
2013-12-18
Lead Sponsor
Takeda
Target Recruit Count
462
Registration Number
NCT01163266

Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

First Posted Date
2010-06-29
Last Posted Date
2013-12-18
Lead Sponsor
Takeda
Target Recruit Count
614
Registration Number
NCT01153009

Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study

Phase 3
Completed
Conditions
Depressive Disorder, Major
Interventions
Drug: Vortioxetine
First Posted Date
2010-06-29
Last Posted Date
2014-05-28
Lead Sponsor
Takeda
Target Recruit Count
1075
Registration Number
NCT01152996

Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.

First Posted Date
2008-09-01
Last Posted Date
2014-03-03
Lead Sponsor
Takeda
Target Recruit Count
301
Registration Number
NCT00744627

Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Phase 3
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Vortioxetine
Drug: Placebo
First Posted Date
2008-08-15
Last Posted Date
2013-12-18
Lead Sponsor
Takeda
Target Recruit Count
560
Registration Number
NCT00735709

An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

First Posted Date
2008-08-13
Last Posted Date
2013-12-18
Lead Sponsor
Takeda
Target Recruit Count
304
Registration Number
NCT00734071
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy